Eva Pike

458 total citations
18 papers, 367 citations indexed

About

Eva Pike is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Eva Pike has authored 18 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Economics and Econometrics, 4 papers in Psychiatry and Mental health and 3 papers in Molecular Biology. Recurrent topics in Eva Pike's work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Schizophrenia research and treatment (3 papers) and Cancer Treatment and Pharmacology (2 papers). Eva Pike is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (4 papers), Schizophrenia research and treatment (3 papers) and Cancer Treatment and Pharmacology (2 papers). Eva Pike collaborates with scholars based in Norway. Eva Pike's co-authors include Marianne Klemp, Torbjørn Wisløff, B Skuterud, Tale Norbye Wien, Annetine Staff, Sigbjørn Smeland, Peter Kierulf, P. K. M. Lunde, Vida Hamidi and Tove Ringerike and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics and British Journal of Clinical Pharmacology.

In The Last Decade

Eva Pike

17 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Pike Norway 9 103 87 62 53 42 18 367
Marshall Sack United States 11 153 1.5× 88 1.0× 39 0.6× 41 0.8× 14 0.3× 12 517
Patrick Mayo Canada 12 25 0.2× 91 1.0× 60 1.0× 19 0.4× 43 1.0× 26 441
Giuliana Martini Italy 11 25 0.2× 60 0.7× 28 0.5× 36 0.7× 17 0.4× 27 584
Claudia B. Karwoski United States 6 52 0.5× 42 0.5× 34 0.5× 37 0.7× 19 0.5× 6 408
Farbod Raiszadeh United States 12 66 0.6× 85 1.0× 18 0.3× 21 0.4× 24 0.6× 37 479
June Han Lee Taiwan 9 28 0.3× 60 0.7× 31 0.5× 91 1.7× 58 1.4× 14 414
Youssef M. Roman United States 13 36 0.3× 63 0.7× 48 0.8× 214 4.0× 52 1.2× 41 434
Shinichiro Nishio Japan 11 25 0.2× 56 0.6× 30 0.5× 62 1.2× 6 0.1× 21 314
William T. Briggs United States 15 274 2.7× 223 2.6× 43 0.7× 12 0.2× 62 1.5× 30 697

Countries citing papers authored by Eva Pike

Since Specialization
Citations

This map shows the geographic impact of Eva Pike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Pike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Pike more than expected).

Fields of papers citing papers by Eva Pike

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Pike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Pike. The network helps show where Eva Pike may publish in the future.

Co-authorship network of co-authors of Eva Pike

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Pike. A scholar is included among the top collaborators of Eva Pike based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Pike. Eva Pike is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Pike, Eva, et al.. (2017). Baroreflex activation therapy for drug-resistant hypertension. A single technology assessment. 3 indexed citations
2.
Pike, Eva, Vida Hamidi, Ingvil Sæterdal, Jan Odgaard‐Jensen, & Marianne Klemp. (2017). Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. BMJ Open. 7(8). e014880–e014880. 18 indexed citations
3.
Pike, Eva, Vida Hamidi, Tove Ringerike, Torbjørn Wisløff, & Marianne Klemp. (2016). More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model. Journal of Clinical Medicine Research. 9(2). 104–116. 47 indexed citations
4.
Sæterdal, Ingvil, et al.. (2016). Health Technology Assessment of Four Drugs for Patients with Metastatic Castration Resistant Prostate Cancer. Duo Research Archive (University of Oslo). 2 indexed citations
5.
Pike, Eva, et al.. (2015). A health technology assessment of the new drugs for inoperable or metastatic malignant melanoma patients. Europe PMC (PubMed Central). 3 indexed citations
6.
Ringerike, Tove, et al.. (2015). The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet]. 1 indexed citations
7.
Pike, Eva, et al.. (2013). Health Technology Assessment of the Different Dialysis Modalities in Norway. Europe PMC (PubMed Central). 5 indexed citations
8.
Wien, Tale Norbye, Eva Pike, Torbjørn Wisløff, et al.. (2012). Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open. 2(1). e000653–e000653. 143 indexed citations
9.
Toverud, Else‐Lydia, Eva Pike, & Lars Walløe. (2009). The National Poison Center in Norway: user satisfaction and a health economic evaluation. European Journal of Clinical Pharmacology. 65(9). 935–940. 6 indexed citations
10.
Pike, Eva, Kari Ann Leiknes, Torbjørn Wisløff, Tove Ringerike, & Marianne Klemp. (2009). Effekt og sikkerhet av første- og annengenerasjons antipsykotika ved schizofreni hos voksne. Duo Research Archive (University of Oslo). 1 indexed citations
11.
Pike, Eva, Kari Ann Leiknes, Torbjørn Wisløff, Tove Ringerike, & Marianne Klemp. (2009). Efficacy and Safety of First-Generation and Second-Generation Anti-Psychotic Drugs for Schizophrenia in Adults: An Overview of Systematic Reviews. Europe PMC (PubMed Central). 4 indexed citations
12.
Sæterdal, Ingvil, Eva Pike, Tove Ringerike, & Marianne Klemp. (2007). Effekt og sikkerhet for SSRI og andre nyere antidepressive legemidler ved depresjon hos voksne. Duo Research Archive (University of Oslo). 1 indexed citations
13.
Pike, Eva, B Skuterud, Peter Kierulf, J. E. Bredesen, & P. K. M. Lunde. (1984). The Relative Importance of Albumin, Lipoproteins and Orosomucoid for Drug Serum Binding. Clinical Pharmacokinetics. 9(Supplement 1). 84–85. 20 indexed citations
14.
Pike, Eva, et al.. (1983). Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.. British Journal of Clinical Pharmacology. 16(3). 233–239. 17 indexed citations
15.
Pike, Eva & B Skuterud. (1982). Plasma binding variations of amitriptyline and nortriptyline. Clinical Pharmacology & Therapeutics. 32(2). 228–234. 19 indexed citations
16.
Pike, Eva, B Skuterud, Peter Kierulf, & P. K. M. Lunde. (1982). Significance of lipoproteins in serum binding variations of amitriptyline, nortriptyline, and quinidine. Clinical Pharmacology & Therapeutics. 32(5). 599–606. 20 indexed citations
17.
Pike, Eva, et al.. (1982). Plasma binding of disopyramide and mono‐N‐dealkyldisopyramide.. British Journal of Clinical Pharmacology. 14(5). 673–676. 24 indexed citations
18.
Pike, Eva, et al.. (1981). Binding and Displacement of Basic, Acidic and Neutral Drugs in Normal and Orosomucoid-deficient Plasma. Clinical Pharmacokinetics. 6(5). 367–374. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026